Singapore’s amazing activity surge in March
The pharmaceutical sector is behind Singapore's manufacturing growth. Everything else is just so gloomy that we've decided to cut our forecasts
| 16.5% |
March manufacturing growthYear-on-year |
| Higher than expected | |
Confounding March data - but largely strong
Confounding the consensus of a 4.9% year-on-year fall, Singapore’s industrial production surged by 16.5% in March. A seasonally-adjusted 22% month-on-month bounce.
This comes on the heels of an 18% YoY (13% MoM SA) surge in non-oil domestic exports (NODX) last month. Yet, all this is in stark contrast with a rather grim picture painted by the manufacturing PMI posting which posted a sharp decline in March, led by a plunge in output and new export order PMI components to the lows since the global financial crisis.
Pharmaceuticals - make hey while the sun shines
Unsurprisingly though, if there is anything left to support economic activity, it is healthcare and pharmaceuticals benefitting from a significant swelling demand.
Like NODX, pharma output was at the core of the March manufacturing surge. The output of the sector advanced by a whopping 127% over a year ago, more than offsetting contractions in other key manufacturing sectors of electronics and petrochemicals by 9% and 7%, respectively.
Among other positives were, precision engineering (up 21%) and transport engineering (up 8%). General manufacturing activity contracted 8% on the year.
1Q20 GDP – smaller fall than initial report
Obviously, the consensus of weak March manufacturing was derived from a -0.5% first-quarter manufacturing GDP growth in the advance GDP estimate for the quarter. However, the advance GDP estimate typically rests on data for the first two months in the quarter. And in the first quarter, March typically sees a bounceback from the Lunar New Year related slack in the first two months, although this time there was little hope of such an outcome given the pervasive economic gloom.
Therefore, -2.2% YoY advance GDP growth estimate clearly missed out the information about an unusual activity strength in the final month in the quarter. Based on today's figure, manufacturing in the first quarter was up by 6.6%, which on its own implies only 0.8% GDP contraction in 1Q, entirely coming from declines in construction and services output.
The final GDP estimate for the quarter is due in mid-May and that will inform about demand-side drags on GDP growth.
2Q20 GDP – going to be worse
The activity may have largely bypassed the Covid-19 pain in the first quarter, but, there is little reason for complacency as the economy is headed for a bigger dent in the current quarter than we earlier thought. The accelerated spread of the disease over last two weeks has forced an extended circuit-breaker until 1 June as announced earlier this week.
We have cut GDP growth forecast for 2Q to -6.8% YoY from -4.5% and for the full-year 2020 growth to -3.7% from -2.6% earlier.
Download
Download article
27 April 2020
Good MornING Asia - 27 April 2020 This bundle contains {bundle_entries}{/bundle_entries} articles"THINK Outside" is a collection of specially commissioned content from third-party sources, such as economic think-tanks and academic institutions, that ING deems reliable and from non-research departments within ING. ING Bank N.V. ("ING") uses these sources to expand the range of opinions you can find on the THINK website. Some of these sources are not the property of or managed by ING, and therefore ING cannot always guarantee the correctness, completeness, actuality and quality of such sources, nor the availability at any given time of the data and information provided, and ING cannot accept any liability in this respect, insofar as this is permissible pursuant to the applicable laws and regulations.
This publication does not necessarily reflect the ING house view. This publication has been prepared solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.
The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.
Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved.
ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam).